Other
Immune Checkpoint Inhibitor
0
Pipeline Programs↗
14
Active Trials↗
6
Companies Involved↗
Immune Checkpoint Inhibitor is an early-stage landscape with 0 programs across 6 companies. The most active players are Astellas, Candel Therapeutics, Inc., EMD Serono Research & Development Institute, Inc..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
28
clinical trials
Completed7 · 25%
Recruiting6 · 21%
Not yet recruiting5 · 18%
Unknown status4 · 14%
Active, not recruiting3 · 11%
Withdrawn2 · 7%
Other1 · 4%
Clinical Trials
Trial Activity
28 trials
GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.
Recruiting·—·Phase 2·NCT06558773·120 enrolled
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
Active, not recruiting·
EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05396833·120 enrolled
EMD Serono Research & Development Institute, Inc.·Phase 1·NCT05396833·120 enrolledThe Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07381634·134 enrolled
Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor
Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06551896·30 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)